Targeting the PI3K/Akt/mTOR pathway in hepatocellul

Future Oncology
7, 1149-1167
DOI: 10.2217/fon.11.95

Citation Report

#	Article	IF	Citations
1	<scp>SB</scp>365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of <scp>PI</scp>3<scp>K</scp>/<scp>A</scp>kt/<scp>mTOR</scp> signaling pathway. Cancer Science, 2012, 103, 1929-1937.	1.7	47
2	Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Science, 2013, 104, 375-382.	1.7	52
3	PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells. Toxicology Letters, 2013, 220, 150-156.	0.4	18
4	Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells. BMC Cancer, 2013, 13, 465.	1.1	7
5	Tâ€ŁAK cellâ€originated protein kinase is essential for the proliferation of hepatocellular carcinoma SMMCâ€7721 cells. Cell Biochemistry and Function, 2013, 31, 736-742.	1.4	12
6	Blocking Autophagic Flux Enhances Matrine-Induced Apoptosis in Human Hepatoma Cells. International Journal of Molecular Sciences, 2013, 14, 23212-23230.	1.8	29
7	The role of Aurora A in hypoxia-inducible factor 1Î±-promoting malignant phenotypes of hepatocelluar carcinoma. Cell Cycle, 2013, 12, 2849-2866.	1.3	30
8	Fatty Acid Esters of Phloridzin Induce Apoptosis of Human Liver Cancer Cells through Altered Gene Expression. PLoS ONE, 2014, 9, e107149.	1.1	46
9	Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Design, Development and Therapy, 2014, 8, 2295.	2.0	23
10	Upregulation of PI3K/AKT/mTOR, FABP5 and PPARÎ²/Î´ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model. Acta Dermato-Venereologica, 2014, 96, 854-6.	0.6	33
11	Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Frontiers in Physiology, 2014, 5, 391.	1.3	9
12	Berberine sensitizes rapamycin-mediated human hepatoma cell death in vitro. Molecular Medicine Reports, 2014, 10, 3132-3138.	1.1	20
13	Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models. Oncogene, 2014, 33, 2717-2727.	2.6	81
14	MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis, 2014, 35, 2748-2755.	1.3	64
15	Hepatitis C virus and microRNAs: miRed in a host of possibilities. Current Opinion in Virology, 2014, 7, 1-10.	2.6	46
16	Industrial natural product chemistry for drug discovery and development. Natural Product Reports, 2014, 31, 35-60.	5.2	210
17	Effects of mTOR-STAT3 on the migra=tion and invasion abilities of hepatoma cell and mTOR-STAT3 expression in liver cancer. Asian Pacific Journal of Tropical Medicine, 2014, 7, 368-372.	0.4	9
18	New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway. Analytical and Bioanalytical Chemistry, 2014, 406, 3743-3754.	1.9	19

#	Article	IF	Citations
19	Effects of Ganfukang (è‚åº·) on expression of connective tissue growth factor and focal adhesion kinase/protein kinase B signal pathway in hepatic fibrosis rats. Chinese Journal of Integrative Medicine, 2014, 20, 438-444.	0.7	6
20	Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research. American Journal of Pathology, 2014, 184, 912-923.	1.9	271
21	Combination of Bevacizumab and Acyclic Retinoid Inhibits the Growth of Hepatocellular Carcinoma Xenografts. Journal of Nutritional Science and Vitaminology, 2014, 60, 357-362.	0.2	4
22	Roles of glucose transporter-1 and the phosphatidylinositol 3-kinase/protein kinase B pathway in cancer radioresistance (Review). Molecular Medicine Reports, 2015, 11, 1573-1581.	1.1	34
23	Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2015, 16, 53-70.	0.8	19
24	PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget, 2015, 6, 10880-10892.	0.8	55
25	Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World Journal of Hepatology, 2015, 7, 1964.	0.8	107
26	The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth. Oncology Reports, 2015, 34, 1708-1716.	1.2	45
27	Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells. International Journal of Molecular Medicine, 2015, 36, 1713-1719.	1.8	39
28	Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2015, 60, 3011-3018.	1.1	18
29	Isoliensinine, a Bioactive Alkaloid Derived from Embryos of Nelumbo nucifera, Induces Hepatocellular Carcinoma Cell Apoptosis through Suppression of NF-ÎºB Signaling. Journal of Agricultural and Food Chemistry, 2015, 63, 8793-8803.	2.4	43
30	MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4). Molecular and Cellular Biochemistry, 2015, 399, 77-86.	1.4	31
31	Expression and clinical significance of Nectin-4 in hepatocellular carcinoma. OncoTargets and Therapy, 2016, 9, 183.	1.0	17
32	Expression and prognostic significance of contactin 1 in human hepatocellular carcinoma. OncoTargets and Therapy, 2016, 9, 387.	1.0	18
33	Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology, 2016, 22, 9069.	1.4	126
34	Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress. PLoS ONE, 2016, 11, e0162634.	1.1	22
35	Acetylcholine induces fibrogenic effects via M2/M3 acetylcholine receptors in nonâ€alcoholic steatohepatitis and in primary human hepatic stellate cells. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 475-483.	1.4	13
36	Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transplantation, 2016, 22, 627-634.	1.3	41

#	Article	IF	Citations
38	Protein-protein interactions among signaling pathways may become new therapeutic targets in liver cancer (Review). Oncology Reports, 2016, 35, 625-638.	1.2	8
39	Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 544-553.	1.3	25
40	Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome. Molecular Cancer Therapeutics, 2016, 15, 2955-2965.	1.9	11
41	Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Scientific Reports, 2016, 6, 20484.	1.6	100
42	Heterogeneity of Hepatocellular Carcinoma. Translational Bioinformatics, 2016, , 371-398.	0.0	0
43	A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle, 2016, 15, 573-583.	1.3	31
44	CD147 is increased in HCC cells under starvation and reduces cell death through upregulating p-mTOR in vitro. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 110-119.	2.2	13
45	MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Letters, 2016, 375, 73-83.	3.2	95
46	MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Tumor Biology, 2016, 37, 8047-8055.	0.8	9
47	Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncology Letters, 2017, 13, 1041-1047.	0.8	156
48	Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression. Biomedicine and Pharmacotherapy, 2017, 93, 40-47.	2.5	41
49	Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish. Scientific Reports, 2017, 7, 45796.	1.6	15
50	Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma. International Journal of Cancer, 2017, 140, 2284-2297.	2.3	28
51	Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicology and Applied Pharmacology, 2017, 315, 90-101.	1.3	50
52	p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis. Cell Cycle, 2017, 16, 1673-1682.	1.3	17
53	Downregulation of BRAF-activated non-coding RNA suppresses the proliferation, migration and invasion, and induces apoptosis of hepatocellular carcinoma cells. Oncology Letters, 2017, 14, 4751-4757.	0.8	17
54	Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology, 2017, 12, 1-10.	1.7	94
55	The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection. Current Drug Targets, 2017, 18, 756-765.	1.0	18

#	Article	IF	Citations
56	Kaempferol Inhibits Angiogenesis by Suppressing HIF-1Î± and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells. Preventive Nutrition and Food Science, 2017, 22, 320-326.	0.7	32
57	The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget, 2017, 8, 57707-57722.	0.8	124
58	Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in hepatocellular carcinoma cells. European Journal of Pharmacology, 2018, 825, 10-18.	1.7	42
59	Effects of Quercetin, Kaempferol, and Exogenous Glutathione on Phospho- and Total-AKTin 3T3-L1 Preadipocytes. Journal of Dietary Supplements, 2018, 15, 814-826.	1.4	12
60	Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway. Biomedicine and Pharmacotherapy, 2018, 98, 134-141.	2.5	15
61	Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. Biomedicine and Pharmacotherapy, 2018, 97, 1282-1288.	2.5	34
62	Neddylation, a novel paradigm in liver cancer. Translational Gastroenterology and Hepatology, 2018, 3, 37-37.	1.5	31
63	Role of the PI3Kâ€'AKTâ€'mTOR pathway in hepatitis B virus infection and replication. Molecular Medicine Reports, 2018, 17, 4713-4719.	1.1	18
64	Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World Journal of Gastroenterology, 2018, 24, 5081-5094.	1.4	58
65	Molecular Action of Herbal Antioxidants in Regulation of Cancer Growth: Scope for Novel Anticancer Drugs. Nutrition and Cancer, 2018, 70, 1199-1209.	0.9	8
66	MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagnostic Pathology, 2018, 13, 85.	0.9	19
67	Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3Î² Signaling Pathway in Human Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2018, 50, 851-867.	1.1	22
68	A new xanthatin analogue 1 Î² -hydroxyl-5 Î± -chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma. Biochimie, 2018, 152, 43-52.	1.3	17
69	The Nogoâ€B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. Journal of Cellular Biochemistry, 2018, 119, 7738-7746.	1.2	5
70	Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells. Scientific Reports, 2018, 8, 10923.	1.6	18
71	Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review. Current Pharmaceutical Biotechnology, 2018, 19, 43-67.	0.9	21
72	Role of nonresolving inflammation in hepatocellular carcinoma development and progression. Npj Precision Oncology, 2018, 2, 6.	2.3	199
73	Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling. Radiology, 2018, 288, 730-738.	3.6	19

#	Article	IF	Citations
74	Integrated multiâ€'omics data analysis identifying novel drug sensitivityâ€'associated molecular targets of hepatocellular carcinoma cells. Oncology Letters, 2018, 16, 113-122.	0.8	5
75	APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Theranostics, 2019, 9, 5246-5260.	4.6	41
76	Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. Archives of Toxicology, 2019, 93, 2219-2235.	1.9	3
77	NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling . OncoTargets and Therapy, 2019, Volume 12, 8537-8552.	1.0	97
78	The antiproliferative effect of spectinabilins from Streptomyces spectabilis on hepatocellular carcinoma cells in vitro and in vivo. Bioorganic Chemistry, 2019, 93, 103311.	2.0	3
79	DPEP1 is a direct target of miR-193a-5p and promotes hepatoblastoma progression by PI3K/Akt/mTOR pathway. Cell Death and Disease, 2019, 10, 701.	2.7	34
80	Upstream regulators of phosphoinositide 3â€kinase and their role in diseases. Journal of Cellular Physiology, 2019, 234, 14460-14472.	2.0	16
81	As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma. Bioscience Reports, 2019, 39, .	1.1	13
82	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110Î² and predicts poor prognosis. Journal of Hematology and Oncology, 2019, 12, 37.	6.9	150
83	Involvement of PI3K/Akt pathway in the protective effect of hesperidin against a chemically induced liver cancer in rats. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22305.	1.4	27
84	Celecoxib alleviates AKT/câ€Metâ€triggered rapid hepatocarcinogenesis by suppressing a novel COXâ€2/AKT/FASN cascade. Molecular Carcinogenesis, 2019, 58, 31-41.	1.3	18
85	P57â€mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma. Liver International, 2019, 39, 147-157.	1.9	19
86	LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway. Journal of Cellular Physiology, 2019, 234, 6908-6916.	2.0	24
87	NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3â€Kinase/Akt Serine/Threonine Kinase and Mitogenâ€Activated Protein Kinase/Extracellular Signalâ€Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma. Hepatology, 2020, 71, 549-568.	3.6	54
89	Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation. European Journal of Pharmacology, 2020, 867, 172788.	1.7	14
90	Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. Journal of Cellular Physiology, 2020, 235, 4146-4152.	2.0	64
91	Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA and Cell Biology, 2020, 39, 355-367.	0.9	13
92	Triterpenoids from Liquidambar Fructus induced cell apoptosis via a PI3K-AKT related signal pathway in SMMC7721 cancer cells. Phytochemistry, 2020, 171, 112228.	1.4	10

#	Article	IF	Citations
93	Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery, 2020, 15, 243-258.	2.5	15
94	Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 9759-9770.	1.0	8
95	The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis. BMC Cancer, 2020, 20, 1167.	1.1	16
96	Pogostemon cablin Triggered ROS-Induced DNA Damage to Arrest Cell Cycle Progression and Induce Apoptosis on Human Hepatocellular Carcinoma In Vitro and In Vivo. Molecules, 2020, 25, 5639.	1.7	10
98	A new clinical prognostic nomogram for liver cancer based on immune score. PLoS ONE, 2020, 15, e0236622.	1.1	7
99	Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma. International Journal of Biological Sciences, 2020, 16, 2835-2852.	2.6	9
101	Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell International, 2020, 20, 165.	1.8	48
102	Research advances on neurite outgrowth inhibitor B receptor. Journal of Cellular and Molecular Medicine, 2020, 24, 7697-7705.	1.6	13
103	Transcriptomic analysis reveals the oncogenic role of S6K1 in hepatocellular carcinoma. Journal of Cancer, 2020, 11, 2645-2655.	1.2	8
104	Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression. Frontiers in Cell and Developmental Biology, 2020, 8, 95.	1.8	48
105	Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma. Molecules, 2020, 25, 2856.	1.7	16
106	Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers, 2020, 12, 491.	1.7	213
107	Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway. Journal of Steroid Biochemistry and Molecular Biology, 2020, 198, 105604.	1.2	44
108	E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway. Cell Death and Disease, 2020, 11, 273.	2.7	48
109	Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers, 2020, 12, 883.	1.7	33
110	Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity. Clinical and Experimental Medicine, 2021, 21, 269-275.	1.9	10
111	Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sciences, 2021, 264, 118642.	2.0	18
112	Integrative analysis of layers of data in hepatocellular carcinoma reveals pathway dependencies. World Journal of Hepatology, 2021, 13, 94-108.	0.8	0

#	Article	IF	Citations
113	Metformin and asarone inhibit HepG2 cell proliferation in a high glucose environment by regulating AMPK and Akt signaling pathway. Future Journal of Pharmaceutical Sciences, 2021, 7, .	1.1	6
114	Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Frontiers in Oncology, 2020, 10, 605057.	1.3	4
115	Tumor aggressiveness is independent of radiation quality in murine hepatocellular carcinoma and mammary tumor models. International Journal of Radiation Biology, 2021, 97, 1140-1151.	1.0	2
116	LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. Laboratory Investigation, 2021, 101, 570-587.	1.7	9
117	Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells byÂblocking VEGF and PI3K/AKT signaling pathways. Molecular Medicine Reports, 2021, 23, .	1.1	16
118	Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus. International Journal of Molecular Sciences, 2021, 22, 3792.	1.8	12
119	Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry, 2021, 28, 3107-3146.	1.2	9
120	Autophagy-Related Gene Pairs Signature for the Prognosis of Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 670241.	1.6	5
121	Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma. Liver Research, 2021, 5, 195-203.	0.5	3
122	Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation. Infectious Agents and Cancer, 2021, 16, 48.	1.2	4
123	GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158920.	1.2	9
124	A novel therapeutic strategy for hepatocellular carcinoma: Immunomodulatory mechanisms of selenium and/or selenoproteins on a shift towards anti-cancer. International Immunopharmacology, 2021, 96, 107790.	1.7	14
125	Transcriptomic analysis links hepatocellular carcinoma (HCC) in HZE ion irradiated mice to a human HCC subtype with favorable outcomes. Scientific Reports, 2021, 11, 14052.	1.6	3
126	Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Frontiers in Oncology, 2021, 11, 666340.	1.3	5
127	Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5â€fluorouracil in vivo by increasing curcumin bioavailability. Phytotherapy Research, 2021, 35, 5823-5837.	2.8	19
128	Caveolin-1 facilitates cell migration by upregulating nuclear receptor 4A2/retinoid X receptor Î±-mediated Î²-galactoside Î±2,6-sialyltransferase I expression in human hepatocarcinoma cells. International Journal of Biochemistry and Cell Biology, 2021, 137, 106027.	1.2	4
129	Identification of Key Regulators of Hepatitis C Virus-Induced Hepatocellular Carcinoma by Integrating Whole-Genome and Transcriptome Sequencing Data. Frontiers in Genetics, 2021, 12, 741608.	1.1	7
130	Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition. Bioorganic and Medicinal Chemistry, 2021, 46, 116346.	1.4	9

#	Article	IF	Citations
131	Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-ÎºB and VEGF/VEGFR2 signaling pathways. Molecular Biology Reports, 2021, 48, 7233-7242.	1.0	8
132	C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene, 2021, 40, 1147-1161.	2.6	46
133	SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma. Clinical Science, 2019, 133, 2085-2105.	1.8	16
134	Progress in research on association between cell signal transduction pathways and hepatocellular carcinoma. World Chinese Journal of Digestology, 2019, 27, 1330-1338.	0.0	3
135	Extract of Pleurotus pulmonarius Suppresses Liver Cancer Development and Progression through Inhibition of VEGF-Induced PI3K/AKT Signaling Pathway. PLoS ONE, 2012, 7, e34406.	1.1	53
136	Choline Plasmalogens Isolated from Swine Liver Inhibit Hepatoma Cell Proliferation Associated with Caveolin-1/Akt Signaling. PLoS ONE, 2013, 8, e77387.	1.1	10
137	Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene. Oncotarget, 2017, 8, 23675-23689.	0.8	43
138	MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget, 2015, 6, 28867-28881.	0.8	174
139	Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma. , 2019, 2, 680-709.		3
140	PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. Current Drug Targets, 2019, 20, 1217-1226.	1.0	167
141	Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?. Current Cancer Drug Targets, 2018, 19, 26-40.	0.8	31
142	Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 995-1001.	0.9	95
143	Molecular targeted therapy for hepatocellular carcinoma: Current and future. World Journal of Gastroenterology, 2013, 19, 6144.	1.4	75
144	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World Journal of Gastroenterology, 2014, 20, 486.	1.4	21
145	Effect of letâ€‘7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma. Oncology Letters, 2020, 21, 96.	0.8	24
146	Quantitative LCâ€“MS/MS uncovers the regulatory role of autophagy in immune thrombocytopenia. Cancer Cell International, 2021, 21, 548.	1.8	3
147	Zingerone suppresses proliferation, invasion, and migration of hepatocellular carcinoma cells by the inhibition of MTDH-mediated PI3K/Akt pathway. Journal of Receptor and Signal Transduction Research, 2022, 42, 409-417.	1.3	4
148	Synthetic Tryptanthrin Derivatives Induce Cell Cycle Arrest and Apoptosis via Akt and MAPKs in Human Hepatocellular Carcinoma Cells. Biomedicines, 2021, 9, 1527.	1.4	4

#	Article	IF	Citations
149	Potential anticancer effects of cyclo(â€Proâ€Tyr) against Nâ€diethyl nitrosamine induced hepatocellular carcinoma in mouse through PI3K/AKT signaling. Environmental Toxicology, 2022, 37, 256-269.	2.1	2
151	Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study. International Journal of Clinical and Experimental Pathology, 2014, 7, 3938-47.	0.5	29
152	Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth. International Journal of Clinical and Experimental Pathology, 2014, 7, 7497-507.	0.5	11
153	Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array. International Journal of Clinical and Experimental Pathology, 2015, 8, 3027-35.	0.5	5
154	New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. American Journal of Cancer Research, 2019, 9, 1329-1353.	1.4	25
155	miR-103 promotes hepatocellular carcinoma cell proliferation and migration in the simulation transition zone of RFA through PI3K/Akt signaling pathway by targeting PTEN. International Journal of Clinical and Experimental Pathology, 2020, 13, 473-479.	0.5	3
156	Sorafenib resistance and autophagy in hepatocellular carcinoma: A concealed threat. Journal of Cancer Research and Practice, 2019, 6, 107.	0.2	5
157	Construction and Comprehensive Analysis of a circRNA-miRNA-mRNA Regulatory Network to Reveal the Pathogenesis of Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2022, 9, 801478.	1.6	3
158	The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. Frontiers in Endocrinology, 2021, 12, 799648.	1.5	9
159	Murine double minute gene 2 (MDM2) promoted hepatocellular carcinoma (HCC) cell growth by targeting fructose-1,6-bisphosphatase (FBP1) for degradation. Biocell, 2022, 46, 1483-1491.	0.4	0
160	Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway. Open Medicine (Poland), 2022, 17, 626-637.	0.6	6
161	Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway. Integrative Cancer Therapies, 2022, 21, 153473542210788.	0.8	6
162	Tumor microenvironment in heptocellular carcinoma. , 2022, , 109-124.		0
163	Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1. Bioengineered, 2022, 13, 5737-5755.	1.4	8
164	Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the <scp>WHSC1</scp>â€mediated <scp>TOP2A</scp>/<scp>PI3K</scp>/<scp>AKT</scp> axis. Kaohsiung Journal of Medical Sciences, 2022, 38, 662-674.	0.8	2
165	miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathology Research and Practice, 2022, 233, 153886.	1.0	53
166	Integrated analysis identified NPNT as a potential key regulator in tumor metastasis of hepatocellular carcinoma. Gene, 2022, 825, 146436.	1.0	6
167	Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway. World Journal of Gastrointestinal Oncology, 2022, 14, 872-886.	0.8	2

#	Article	IF	Citations
168	PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers, 2022, 2022, 1-18.	0.6	1
169	Case report: Urgent liver pathologies: All in one. Frontiers in Surgery, 0, 9, .	0.6	2
170	Up-Regulation of RACGAP1 Promotes Progressions of Hepatocellular Carcinoma Regulated by GABPA via PI3K/AKT Pathway. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-16.	1.9	6
171	microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. Cell Cycle, 2022, 21, 2651-2663.	1.3	3
172	Circular RNA hsa_circ_0062682 Binds to YBX1 and Promotes Oncogenesis in Hepatocellular Carcinoma. Cancers, 2022, 14, 4524.	1.7	5
174	Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 203-222.	8.2	113
175	Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives. Transplantation Proceedings, 2022, 54, 2593-2597.	0.3	1
176	Nanosized zingerone-triggered anti-angiogenesis contributes to tumor suppression in human hepatocellular carcinoma. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2023, 658, 130697.	2.3	1
177	Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. Human Cell, 2023, 36, 296-311.	1.2	9
178	Transcriptome analysis revealed the role of mTOR and MAPK signaling pathways in the white strain of Hypsizygus marmoreus extracts-induced cell death of human hepatoma Hep3B cells. Frontiers in Pharmacology, 0, 13, .	1.6	2
179	Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 2022, 10, 3202.	1.4	26
180	Cadmium modulates steatosis, fibrosis, and oncogenic signaling in liver cancer cells by activating notch and <scp>AKT</scp>/<scp>mTOR</scp> pathways. Environmental Toxicology, 2023, 38, 783-797.	2.1	8
181	Long-term effect of anesthesia choice on patients with hepatocellular carcinoma undergoing open liver resection. Frontiers in Oncology, 0, 12, .	1.3	2
182	Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer and Metastasis Reviews, 2023, 42, 629-652.	2.7	13